Kromek Group PLC
02 October 2026
2 October 2026
Kromek Group plc
(“Kromek” or the “Group”)
Notice of AGM and Publication of Annual Report
Directorate Changes
Update on Bank Facility
Kromek (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, gives notice of its Annual General Meeting (“AGM”) and publication of annual report, announces directorate changes and provides an update on its bank facility.
Notice of AGM and publication of annual report
The Group’s AGM will be held at 9.30am on Friday 23 October 2026 in the Kromek ‘Biosecurity’ Boardroom at Explorer 1 Building, North East Technology Park (NETPark), Thomas Wright Way, Sedgefield, County Durham, TS21 3FF.
The notice of AGM and form of proxy, alongwith the Group’s annual report and accounts for the year ended 30 April 2026, have been published on the ‘Company Documents & Reports’ page in the Investor Relations section of the Group’s website at https://investors.kromek.com/company-documents. The documents are being posted today to those shareholders who have requested paper communications.
Directorate changes
Kromek announces that Chris Wilkes, who has served as Non-Executive Director since 2017, will be retiring from the Board and Jane Pearce will be appointed as a Non-Executive Director of the Company with effect from the conclusion of the AGM. Jane will assume the role of Chair of the Audit Committee.
Jane, who is a qualified chartered accountant, brings significant senior level financial markets experience to the Board. She spent a number of years as a Technology Equity Analyst and as an Equity Strategist at leading investment banks in the City of London, including HSBC, Lehman Brothers and Nomura International. She is currently Chair of Morgan Stanley Investment Management Limited and a Non-executive Director of Morgan Stanley Bank International Limited, Morgan Stanley & Co International plc and Polar Capital Technology Trust, a FTSE 100-listed investment trust where she chairs the Audit Committee.
Update on bank facility
Further to its final results announcement of 14 September 2026, the Group is pleased to confirm that it has finalised an agreement for a £3.0m expansion to its revolving credit facility (“RCF”) with HSBC. The increased RCF facility will be used to support and assist working capital requirements.
Rakesh Sharma, Chairman of Kromek, said: “On behalf of the Board, I would like to express our sincere thanks to Chris for his contribution and guidance over the last nine years, and we wish him well in his future endeavours. I am delighted to welcome Jane to Kromek, who will bring significant financial markets as well as corporate governance experience. I am also pleased to confirm the extension to our RCF with HSBC bank, which will support our working capital and, in particular, our growth in Advanced Imaging.”
Enquiries
|
Investor questions on this announcement |
|
|
We encourage all investors to share questions on this announcement via our investor hub |
|
|
|
|
|
Kromek Group plc |
|
|
Arnab Basu, CEO Claire Burgess, CFO |
+44 (0)1740 626 060 |
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Broker) |
|
|
Geoff Nash/Giles Balleny/Seamus Fricker – Corporate Finance Andrew Burdis – ECM Michael Johnson – Sales |
+44 (0)20 7220 0500
|
|
|
|
|
Gracechurch Group (Financial PR) |
|
|
Harry Chathli/Claire Norbury |
+44 (0)20 4582 3500 |
Engage with the Kromek management team directly by asking questions, watching videosummaries and seeing what other shareholders have to say. Navigate to our interactive investorhub here: https://investors.kromek.com/
Subscribe to our news alert service: https://investors.kromek.com/auth/signup
Kromek Group plc
Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.
The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.
In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.
The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.
Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.
Regulatory Disclosures:
The following information regarding the appointment of Jane Osmani-Pearce (née Pearce), aged 58 is disclosed under Schedule 2(g) of the AIM Rules for Companies:
|
Current directorships: |
Morgan Stanley Investment Management Morgan Stanley &Co International Ltd Morgan Stanley &co International plc Morgan Stanley Bank International Ltd Polar Capital Technology Trust plc 37 Kempsford Garden Residents ltd |
|
|
|
|
Historic directorships and partnerships in previous 5 years: |
Shires Income plc Audit and Risk Committee of St Andrews University |
Jane was a director of Shires Income plc when it was dissolved in March 2026 under a section 110 liquidation and rollover into an existing vehicle (Aberdeen Equity Income), with no outstanding amounts due to creditors.
Jane holds no shares or share options in Kromek.
There are no further disclosures required under Schedule 2(g) of the AIM Rules for Companies.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.